Effect of continuous exenatide infusion on cardiac function and peri-operative glucose control in patients undergoing cardiac surgery: A single-blind, randomized controlled trial

Autor: Jaroslav Lindner, Jarmila Křížová, Martin Haluzik, Jana Klouckova, Petr Kopecký, Michaela Diamant, Milos Dobias, Milos Mraz, Michal Lips
Přispěvatelé: Internal medicine, ACS - Diabetes & metabolism
Rok vydání: 2017
Předmět:
Male
Endocrinology
Diabetes and Metabolism
medicine.medical_treatment
030204 cardiovascular system & hematology
law.invention
Hospitals
University
Ventricular Dysfunction
Left
0302 clinical medicine
Endocrinology
Postoperative Complications
Randomized controlled trial
law
Medicine
Insulin
Single-Blind Method
Coronary Artery Bypass
Infusions
Intravenous
Intraoperative Complications
Czech Republic
Ejection fraction
Incidence
Heart
Cardiac surgery
Anesthesia
Drug Therapy
Combination
Female
medicine.drug
Cardiac function curve
Risk
medicine.medical_specialty
Cardiotonic Agents
030209 endocrinology & metabolism
Placebo
Incretins
Proof of Concept Study
Glucagon-Like Peptide-1 Receptor
Perioperative Care
03 medical and health sciences
Internal Medicine
Humans
Hypoglycemic Agents
Aged
business.industry
Venoms
Perioperative
Hypoglycemia
Hyperglycemia
Exenatide
business
Peptides
Zdroj: Lipš, M, Mráz, M, Kloučková, J, Kopecký, P, Dobiáš, M, Křížová, J, Lindner, J, Diamant, M & Haluzík, M 2017, ' Effect of continuous exenatide infusion on cardiac function and peri-operative glucose control in patients undergoing cardiac surgery : A single-blind, randomized controlled trial ', Diabetes, Obesity and Metabolism, vol. 19, no. 12, pp. 1818-1822 . https://doi.org/10.1111/dom.13029
Diabetes, Obesity and Metabolism, 19(12), 1818-1822. Wiley-Blackwell
ISSN: 1463-1326
1462-8902
DOI: 10.1111/dom.13029
Popis: We performed a randomized controlled trial with the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide as add-on to standard peri-operative insulin therapy in patients undergoing elective cardiac surgery. The aims of the study were to intensify peri-operative glucose control while minimizing the risk of hypoglycaemia and to evaluate the suggested cardioprotective effects of GLP-1-based treatments. A total of 38 patients with decreased left ventricular systolic function (ejection fraction ≤50%) scheduled for elective coronary artery bypass grafting (CABG) were randomized to receive either exenatide or placebo in a continuous 72-hour intravenous (i.v.) infusion on top of standard peri-operative insulin therapy. While no significant difference in postoperative echocardiographic variables was found between the groups, participants receiving exenatide showed improved peri-operative glucose control as compared with the placebo group (average glycaemia 6.4 ± 0.5 vs 7.3 ± 0.8 mmol/L; P
Databáze: OpenAIRE
Externí odkaz: